Objective: This study investigated pre- and post-treatment tumor and lymph node dimension response ratesand differences between side-effect profiles in patients with locally advanced inoperable nonsmall-cell lungcancer (NSCLC) receiving radiotherapy (RT) and concurrent chemotherapy (CT).Materials and Methods: A total of 30 inoperable patients who had not previously received RT and having amean age of 58.73±8.65 years with sufficient hematological reserves and normal hepatic and renal functionswere included in the study. Those with pleural effusion, supraventricular lymph node metastasis, and N3lymph node involvement were excluded. Group I (n=15) received a 21-day 75 mg/m2 cisplatin (D1) and 15mg/m2 vinorelbine (D1, D8), whereas Group II (n=15) received 45 mg/m2 paclitaxel and AUC2 carboplatinweekly. RT was administered using a linear accelerator device with the 3D conformal RT technique at 6-18MV energy with a 1.8-2 Gy fraction for 6-7 weeks.Results: Patients were randomized into Group I receiving RT and concurrent cisplatin–vinorelbine and GroupII receiving weekly paclitaxel–carboplatin CT. Pre- and post-treatment tumor and lymph node dimensionssignificantly differed in both groups (p<0.001 and p<0.01, respectively). No significant change was observedin post-RT tumor and lymph node dimensions in terms of applied CT regimens (p>0.05).Conclusion: The significant response achieved with concurrent RT and CT in groups I and II in the localadvanced stage of NSCLC is important for local tumor control. Responses to treatment in the group of twoarms did not differ.